Table 2.
Fatty acid | anti-miR-C/anti-miR-C | anti-miR-C/anti-miR-26a | anti-miR-C/anti-miR-26b | anti-miR -26a /-26b | NC | siCTDSP1 | siCTDSP2 | siCTDSPL |
---|---|---|---|---|---|---|---|---|
C16:0 (%) | 27.85 + 0.53c | 32.51 + 0.28ab | 31.6 + 0.30b | 34.24 + 0.43a | 28.12 + 0.23B | 32.99 + 0.20A | 31.99 + 0.18A | 29.16 + 0.12AB |
C16:1 (%) | 4.43 + 0.21a | 3.13 + 0.17b | 2.23 + 0.09c | 1.8 + 0.08d | 4.03 + 0.21A | 2.99 + 0.24B | 3.13 + 0.04B | 3.94 + 0.14A |
C18:0 (%) | 12.86 + 0.31b | 16.25 + 0.21a | 16.22 + 0.23a | 16.08 + 0.28a | 13.26 + 0.23B | 12.94 + 0.28B | 14.06 + 0.21A | 14.57 + 0.15A |
C18:1 (%) | 53.01+ 0.56a | 46.43 + 0.39b | 48.66 + 0.63ab | 46.22 + 0.67b | 52.74 + 0.26A | 49.02 + 0.13B | 49.23 + 0.16B | 50.24 + 0.17AB |
C18:2 (%) | 1.85 + 0.11a | 1.68 + 0.12a | 1.28 + 0.15b | 1.66 + 0.13a | 1.85 + 0.11A | 2.06 + 0.09A | 1.59 + 0.06B | 2.09 + 0.07A |
SFA* (%) | 40.71 | 48.76 | 47.83 | 50.32 | 41.38 | 45.93 | 46.05 | 43.73 |
UFA** (%) | 59.29 | 51.24 | 52.17 | 49.68 | 58.62 | 54.07 | 53.95 | 56.27 |
UFA/SFA | 1.46 | 1.05 | 1.09 | 0.99 | 1.42 | 1.18 | 1.17 | 1.29 |
SFA: saturated fatty acids,
UFA: unsaturated fatty acids.
GMEC were co-transfected with 120 nM anti-miRNA oligonucleotides (60 nM each) or transfected with 60 nM siRNA. Relative fatty acid composition is calculated as percentages relative to the total of these fatty acids identified. All experiments were performed in triplicate and repeated 3 times (n = 9). Values are presented as means ± SEM; a, b: significant difference among treatments in anti-miRNA group (P < 0.05).A, B: significant difference among treatments in siRNA group (P < 0.05).